Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension;Tedavi almami{dotless}ş primer hipertansif hastalarda valsartani{dotless}n serum ghrelin düzeyi ve sol ventrikül kitle indeksi üzerindeki etkileri

Anadolu Kardiyoloji Dergisi

Volumn 14, Issue 3, 2014, Pages 234-238

  Meriç, Coşkun ^a   Aydoǧdu, Aydoǧan ^a   Taşçi, Ilker ^a   Deniz, Ferhat ^a   Baysan, Oben ^b   Serdar, Muhittin ^a   Saǧlam, Kenan ^a   Azal, Ömer ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b GÜVEN HOSPITAL   (Turkey)

Author keywords

Ghrelin; Hypertension; Left ventricular mass index; Valsartan

Indexed keywords

GHRELIN; VALSARTAN; ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE; BODY MASS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; INTERVENTION STUDY; MALE; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; TRANSTHORACIC ECHOCARDIOGRAPHY; BLOOD; CLINICAL TRIAL; ECHOCARDIOGRAPHY; ECHOGRAPHY; HYPERTROPHY, LEFT VENTRICULAR; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; ECHOCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GHRELIN; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VALSARTAN;

EID: 84901711511     PISSN: 13028723     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2014.4738     Document Type: Article

References (31)

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60. [CrossRef]
2. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, et al. Stomach is a major source of circulating ghrelin and feeding state determines plasma ghrelin-like immuno reactivity levels in humans. J Clin Endocrinol Metab 2001; 86: 4753-8. [CrossRef]
3. Volante M, Allia E, Gugliotta P, Funaro A, Broglio F, Deghenghi R, et al. Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab 2002; 87: 1300-8. [CrossRef]
4. Dezaki K, Sone H, Yada T. Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther 2008; 118: 239-49. [CrossRef]
5. Seppo M, Eija K, Sohvi H, Heikki K, Antero K, Olavi U. Low plasma ghrelin is associated with insulin resistance, hypertension, and prevalence of type 2 diabetes. Diabetes 2003; 52: 2546-53. [CrossRef]
6. Matsumura K, Tsuchihashi T, Fujii K, Abe I, Iida M. Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 2002; 40: 694-9. [CrossRef]
7. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280: 1483-7.
8. Nagaya N, Miyatake K, Uematsu M, Oya H, Shimizu W, Hosoda H, et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 2001; 86: 5854-9. [CrossRef]
9. Aoki H, Nakata M, Dezaki K, Lu M, Gantulga D, Yamamoto K, et al. Ghrelin counteracts salt-induced hypertension via promoting diuresis and renal nitric oxide production in Dahl rats. Endocr J 2013; 60: 571-81. [CrossRef]
10. Chang L, Ren Y, Liu X, Li WG, Yang J, Geng B, et al. Protective effects of ghrelin on ischemia/reperfusion injury in isolated rat heart. J Cardiovasc Pharmacol 2004; 43: 165-70. [CrossRef]
11. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104: 1430-5. [CrossRef]
12. Wiley KE, Davenport AP. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 2002; 136: 1146-52. [CrossRef]
13. The seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-7). JAMA 2003; 289: 2560-71. [CrossRef]
14. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assesment of left ventricular hypertrophy: comparision to necropsy findings. Am J Cardiol 1986; 57: 450-8. [CrossRef]
15. Rosenthal J. Systolic and diastolic cardiac function in hypertension. J Cardiovasc Pharmacol 1992; 19: 112-5. [CrossRef]
16. Shiiya T, Nakazato M, Mizuta M, Matsukara S, Mondal MS, Tanaka M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002; 87: 240-4. [CrossRef]
17. David E, David S, Frayo RS, Breen PA, Marina K, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-30. [CrossRef]
18. Tschöp M, Weyer CW, Tataranni PA, Devanarayan V, Ravussin E, Heiman M. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-9. [CrossRef]
19. Pöykkö SM, Kellokoski E, Hörkkö S, Kauma H, Kesäniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003; 52: 2546-53. [CrossRef]
20. Matsumura K, Averill DB, Ferrario CM. Angiotensin II acts at AT1 receptors in the nucleus of the solitary tract to attenuate the baroreceptor reflex. Am J Physiol 1998; 275: 1611-9.
21. Matsumura K, Tsuchihashi T, Fujii K, Iida M. Neural regulation of blood pressure by leptin and the related peptides. Regul Pept 2003; 114: 79-86. [CrossRef]
22. Lin Y, Matsumura K, Fukuhara M, Kagiyama S, Fujii K, Iida M. Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 2004; 43: 977-82. [CrossRef]
23. Karcz-Socha I, Zwirska-Korczala K, Zembala M, Borgiel-Marek H, Karcz K. Ghrelin PYY 3-36 serum changes in left ventricular hypertrophic, insulin-resistant, hypertensive obese patients. Obes Facts 2011; 4: 386-92. [CrossRef]
24. Okumura H, Nagaya N, Enomoto M, Nakagawa E, Oya H, Kangawa K. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol 2002; 39: 779-83. [CrossRef]
25. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006; 47: 1108-16. [CrossRef]
26. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007; 49: 1455-61. [CrossRef]
27. Skoczylas A, Adamczak M, Chudek J, Wiecek A. Cilazapril increases plasma ghrelin concentration in obese patients with arterial hypertension. Endokrynol Pol 2010; 61: 21-7.
28. Hamada N, Nishi Y, Tajiri Y, Setoyama K, Kamimura R, Miyahara K, et al. Disrupted regulation of ghrelin production under antihypertensive treatment in spontaneously hypertensive rats. Circ J 2012; 76: 1423-9. [CrossRef]
29. Vartiainen J, Rajala U, Jokelainen J, Keinänen-Kiukaanniemi S, Kesäniemi YA, Ukkola O. Serum ghrelin and the prediction of the development of impaired glucose regulation and type 2 diabetes in middle-aged subjects. J Endocrinol Invest 2010; 33: 496-500.
30. Greenman Y, Rouach V, Limor R, Gilad S, Stern N. Testosterone is a strong correlate of ghrelin levels in men and postmenopausal women. Neuroendocrinology 2009; 89: 79-85. [CrossRef]
31. Öner Iyidoǧan Y, Koçak H, Gürdöl F, Öner P, Issever H, Esin D. Circulating ghrelin levels in obese women: a possible association with hypertension. Scand J Clin Lab Invest 2007; 67: 568-76. [CrossRef]